Topic: Amgen

The Department of Health and Human Services (HHS) announced a $290 million purchase of the drug Nplate from Amgen to treat blood cell injuries caused by radiological or nuclear emergencies. While officials claim the procurement is part of a long-planned preparedness strategy, skeptics suggest the timing is suspicious given current geopolitical tensions. The move is characterized by some as a financial payout to a pharmaceutical company that did not profit from the COVID-19 vaccine market.

Scientist Julia Bach explained that the PCR test, while accurate at detecting genomic material, cannot determine if a virus is active or replicating. This reliance on PCR as a "gold standard" has effectively changed the medical definition of being "sick" or "infected" to include asymptomatic individuals. Critics argue that a cell-based assay would be a more appropriate diagnostic tool for determining actual illness.

A comparison is drawn between modern medical diagnosis and 15th-century witch-hunting criteria, such as birthmarks or living alone. Additionally, a report by Amgen's Glenn Begley found that 47 out of 53 landmark cancer research papers could not be replicated, highlighting systemic corruption in scientific funding.